Ignite Creation Date:
2024-07-17 @ 11:11 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06475209
Status:
RECRUITING
Last Update Posted:
2024-06-26
First Post:
2024-06-20
Brief Title:
Adebrelimab Apatinib in SCLC Maintenance Therapy
Sponsor:
Tang-Du Hospital
Organization:
Tang-Du Hospital
Study Overview
Official Title:
Observational Study on the Efficacy and Safety of Adebrelimab Combined With Apatinib in Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This prospective clinical study aims to evaluate and observe the efficacy and safety of Atezolizumab combined with Apatinib in maintenance therapy for extensive-stage small cell lung cancer using a single-arm trial design
The study is planned to be conducted in Shaanxi Province China with an initial target enrollment of 60 patients The study commenced in February 2024 and recruitment is expected to conclude around December 2025 with the trial anticipated to end by December 2026 Assuming no occurrences such as withdrawal of informed consent by subjects intolerable adverse drug reactions or investigator-assessed unsuitability for further participation each participants estimated duration of study treatment will continue until radiographically confirmed tumor progression
The study is planned to be conducted in Shaanxi Province China with an initial target enrollment of 60 patients The study commenced in February 2024 and recruitment is expected to conclude around December 2025 with the trial anticipated to end by December 2026 Assuming no occurrences such as withdrawal of informed consent by subjects intolerable adverse drug reactions or investigator-assessed unsuitability for further participation each participants estimated duration of study treatment will continue until radiographically confirmed tumor progression
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None